Quince Therapeutics (QNCX) director takes 21,810 stock options in lieu of cash

Rhea-AI Filing Summary

Quince Therapeutics director Christopher J. Senner reported a grant of 21,810 stock options on January 2, 2026. The derivative award is a director stock option with a $3.00 exercise price and an expiration date of January 2, 2036, covering 21,810 shares of common stock. Following this grant, he beneficially owns 21,810 derivative securities directly.

The options will vest in equal quarterly installments over a one-year period. Senner elected to receive these options in lieu of the annual director cash retainer for 2026 under the company’s Outside Director Compensation Policy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Senner Christopher J.

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$3	01/02/2026		A		21,810		(1)	01/02/2036	Common Stock	21,810	$0	21,810	D

Explanation of Responses:

1. The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.

	/s/ Brendan Hannah as attorney-in-fact for Christopher J. Senner	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Quince Therapeutics (QNCX) report for Christopher J. Senner?

Quince Therapeutics reported that director Christopher J. Senner received a grant of 21,810 director stock options on January 2, 2026, reported on a Form 4.

What are the key terms of Christopher J. Senner’s 2026 stock option grant at Quince Therapeutics (QNCX)?

The grant is a director stock option to buy 21,810 shares of common stock at an exercise price of $3.00 per share, expiring on January 2, 2036.

How do Christopher J. Senner’s Quince Therapeutics (QNCX) options vest?

The shares subject to the option vest in equal quarterly installments over a one-year period from the grant date.

Why did Christopher J. Senner receive stock options instead of cash at Quince Therapeutics (QNCX)?

Senner elected to receive stock options in lieu of the annual director cash retainer for 2026, as provided under Quince Therapeutics’ Outside Director Compensation Policy.

How many Quince Therapeutics (QNCX) derivative securities does Christopher J. Senner beneficially own after this transaction?

After the reported transaction, Senner beneficially owns 21,810 derivative securities (director stock options), held directly.

Is the reported Quince Therapeutics (QNCX) Form 4 transaction a purchase or an award?

The Form 4 shows an award of director stock options coded as an acquisition (Code A), with no cash price paid for the grant itself.